Linked Life Data

19480781

Source:http://linkedlifedata.com/resource/pubmed/id/19480781

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2009-6-1
pubmed:abstractText
Statin therapy reduces the incidence of cardiovascular (CV) disease by 30-40%. However, some risk of unprevented CV complications still persists. Thus, new drugs that when associated to the statins favorably modify the lipid profile and further reduce CV risk are needed. In this clinical commentary, we review the role of other lipids (HDL cholesterol and triglycerides) in CV risk and those potentially useful agents that could be added to statins. Fibrates are especially effective to decrease triglycerides, whilst niacin has a global effect, decreasing LDL cholesterol and triglycerides and is the most effective drug to increase HDL cholesterol. The association of statins plus niacin may be the immediate future to tackle the comprehensive treatment of dyslipidemia and potentially further reduce the risk of CV disease.
pubmed:language
spa
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0014-2565
pubmed:author
pubmed:issnType
Print
pubmed:volume
209
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
241-4
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
[New challenges in the treatment of dyslipidemia and cardiovascular risk].
pubmed:affiliation
Servicio de Medicina Interna, Hospital Universitario de La Princesa, Madrid, España.
pubmed:publicationType
Journal Article, English Abstract